8-K: Aquestive Therapeutics Details Anaphylm Launch, $85M Capital Raise

Aquestive Therapeutics presented its strategic pipeline, including Anaphylm's PDUFA date and a recent $85 million equity raise, at the H.C. Wainwright 27th Annual Global Investor Conference.

Summary

• Aquestive Therapeutics is advancing its pipeline, including Anaphylm (dibutepinephrine) Sublingual Film for severe allergies, Libervant (diazepam) Buccal Film for acute repetitive seizures, and AQST-108 (epinephrine) Topical Gel for alopecia areata.
• Anaphylm has a PDUFA action date scheduled for January 31, 2026, and is positioned as the first and only non-device based, orally delivered epinephrine product candidate.
• The U.S. epinephrine market is projected to grow from approximately $800 million in 2024 to $2 billion by 2031, driven by increasing allergy prevalence and demand for better solutions.
• The company completed an $85 million equity raise on August 14, 2025, and secured strategic funding with RTW Investments, LP, extending its cash runway into 2027.
• Anaphylm is designed to work quickly, reaching peak absorption in 12 minutes and therapeutic blood concentrations in as little as 5 minutes.
• Market research indicates strong preference for film dosing, with 80% of patients/caregivers preferring non-injection methods and 95% of HCPs believing a film-dosing option fills an unmet need.
• The company has over 20 years of experience, 150+ employees, 3 drug approvals, and over 2.5 billion PharmFilm doses shipped worldwide.
• Pipeline assets, including Anaphylm, Libervant, and AQST-108, have a potential for over $1.5 billion in peak annual net sales.

Sentiment

Score: 8

Explanation: The filing presents a strong positive outlook, highlighting a clear path to market for its lead product Anaphylm, significant market opportunity, successful capital raise, and extended cash runway. The pipeline is diversified, and market research supports the product's potential. While pre-approval, the progress and financial strengthening are highly favorable.

Positives

• Anaphylm (dibutepinephrine) Sublingual Film has a clear PDUFA action date of January 31, 2026, indicating a defined path to potential market approval.
• The U.S. epinephrine market is projected for significant growth, from ~$800 million in 2024 to ~$2 billion by 2031, presenting a substantial opportunity for Anaphylm.
• A successful equity raise of $85 million on August 14, 2025, combined with strategic funding, has bolstered the balance sheet and provides a cash runway into 2027.
• Anaphylm offers a novel, needle-free, device-free, and orally delivered epinephrine solution, addressing key patient and prescriber pain points like inconvenience and fear of needles.
• Clinical data shows Anaphylm achieves rapid therapeutic blood concentrations (in 5 minutes) and peak absorption (in 12 minutes), crucial for anaphylaxis treatment.
• Strong market interest exists for film-dosing options, with 95% of healthcare providers believing it fills an unmet need and 85% indicating they would prescribe it.
• The company has a diversified pipeline with multiple growth drivers, including Libervant and AQST-108, targeting significant annual revenue opportunities.
• Extensive go-to-market activities are underway for Anaphylm, including KOL engagement, market research, and strategic planning for payer access and patient services.

Risks

• Delays or changes to the timing, cost, and success of product development activities and clinical trials, including for Anaphylm and AQST-108.
• Failure to receive regulatory approval for product candidates, including Anaphylm, or delays in the FDA approval process, such as NDA acceptance.
• The company's clinical data may not be sufficient for FDA approval of Anaphylm, particularly regarding pharmacokinetic (PK) and pharmacodynamic (PD) comparability.
• The FDA may require additional clinical studies for Anaphylm approval based on comments from Type C meeting minutes.
• Uncertainty regarding U.S. market access for Libervant upon the expiration of orphan drug market exclusivity for a competing nasal spray product in January 2027.
• Risks associated with the success of competing products, including generics, and the ability to develop effective market access, sales, and marketing capabilities.
• Insufficient capital and cash resources to satisfy short-term and longer-term liquidity requirements, including principal payments on 13.5% Notes in 2026 and funding future development and commercial activities.
• Manufacturing capabilities may not be sufficient to support demand for product candidates if approved.
• Eroding market share for Suboxone, which accounts for a substantial part of current operating revenue.
• Risks related to intellectual property rights, patent issuance, and potential infringement claims.
• Changes in laws or regulations affecting the business, including product pricing, reimbursement, or access.

Future Outlook

The company anticipates the potential FDA approval of Anaphylm by its PDUFA action date of January 31, 2026, followed by a strategic commercial launch focusing on allergists and pediatricians. It also plans for potential ex-US approval filings for Anaphylm in Q4 2025. The AdrenaVerse pipeline, including AQST-108, is expected to advance through clinical development with an IND submission and Phase 2a trial initiation planned. The company projects significant growth in the U.S. epinephrine market and aims to leverage its strengthened balance sheet to fund future clinical development and commercial activities, extending its cash runway into 2027.

Management Comments

• The company is focused on advancing medicines, solving problems, and improving lives through its innovative drug delivery platforms.
• Management believes Anaphylm represents a novel approach to epinephrine delivery, offering a needle-free, easy-to-use, and rapidly acting solution that addresses significant unmet needs in anaphylaxis treatment.
• The leadership team is dedicated to executing the go-to-market strategy for Anaphylm, including engaging key opinion leaders, conducting market research, and building commercial capabilities.
• The recent capital raise and strategic funding validate the commercial promise of Anaphylm and provide the necessary resources to achieve key milestones and prepare for product launches.

Industry Context

The U.S. epinephrine market is experiencing significant growth, projected to reach $2 billion by 2031, driven by increasing allergy prevalence and a demand for more convenient and effective solutions beyond traditional auto-injectors. Anaphylm's non-device, orally delivered approach positions it to potentially disrupt the market by addressing common barriers to adherence and use of existing epinephrine auto-injectors, such as fear of needles, bulkiness, and forgetfulness. This aligns with a broader industry trend towards patient-friendly drug delivery methods and personalized medicine.

Stakeholder Impact

• Shareholders: Potential for significant value creation through pipeline advancements, successful product launches, and a strengthened financial position.
• Patients: Access to novel, needle-free, and convenient treatment options for severe allergies (Anaphylm) and acute repetitive seizures (Libervant), potentially improving adherence and outcomes.
• Healthcare Providers: New prescribing options that address unmet needs in epinephrine delivery and seizure management, supported by positive market research.
• Employees: Continued growth and stability for the company, particularly for the 150+ employees based in Indiana and New Jersey, as pipeline assets advance towards commercialization.

Next Steps

• Await PDUFA action date for Anaphylm on January 31, 2026.
• Execute launch readiness activities for Anaphylm throughout 2025 and 2026, including unbranded medical education and talent acquisition.
• Continue to execute the go-to-market plan for Anaphylm, driving awareness among prescribers, engaging with payers, and collaborating with advocacy groups.
• Facilitate market access with payers and focus on key prescribers during the initial launch of Anaphylm.
• Submit an Investigational New Drug (IND) application for AQST-108 (epinephrine) Topical Gel.
• Initiate a Phase 2a clinical trial for AQST-108 for the treatment of patients with alopecia areata.
• Pursue potential ex-US approval filings for Anaphylm in Q4 2025.

Key Dates

Recommendation

The company demonstrates a clear and well-funded path to market for its lead asset, Anaphylm, which addresses a significant unmet need in a growing market. The successful $85 million capital raise and strategic funding provide a strong cash runway into 2027, mitigating near-term liquidity concerns. With a PDUFA date set for January 2026 and positive market reception indicated by research, the potential for regulatory approval and commercial success is high. The diversified pipeline further enhances long-term growth prospects, making this an attractive investment opportunity for a seasoned investor.

Keywords

Aquestive Therapeutics, Anaphylm, dibutepinephrine, sublingual film, epinephrine, anaphylaxis, Libervant, diazepam, buccal film, acute repetitive seizures, AQST-108, alopecia areata, AdrenaVerse, PharmFilm, biotech, pharmaceutical, drug delivery, FDA, PDUFA, capital raise, investor conference